-

Digbi Health Introduces Industry-First Medically Managed Weight Loss Program that Leverages Precision Biology to Improve GLP-1 Drug Effectiveness, Adherence, and Tapering

Available nationwide, this program offers employers a science-backed, cost-effective solution for managing obesity, gastrointestinal (GI) health, and related metabolic conditions.

PALO ALTO, Calif.--(BUSINESS WIRE)--Digbi Health expands its award-winning multi-condition telehealth platform with the introduction of a comprehensive solution that leverages genetic insights, gut microbiome analysis, and continuous glucose monitors (CGMs) to improve the effectiveness of GLP-1 drugs and guarantee successful medication tapering.

Key Features of Digbi Health’s Medically Managed Program:

  • Comprehensive GI Health Screening and Care: The program offers in-depth GI clinical assessments, tracking, and at-home gut microbiome testing to address GI adverse effects that impact the adherence and effectiveness of GLP-1s.
  • Personalized Treatment: Digbi uses GLP-Fit (tm) to determine the best treatment path and delivers personalized care. The program provides AI-supported real-time nutritional guidance to improve muscle and glucose health.
  • Convenience and adaptability: Patients can access their existing physicians or access Digbi Health’s telehealth platform for GLP-1 prescriptions and clinical care. The program accommodates both branded and compounded GLP-1 drugs, ensuring tailored care to meet the needs of employers, physicians, and patients.

“At Digbi Health, we leverage the gut microbiome to boost the body’s natural production of GLP-1, enabling patients to taper off medication while maintaining their health and weight loss,” said Ranjan Sinha, CEO of Digbi Health. “Our ability to combine obesity, GI, and cardiometabolic care into a single platform simplifies management for employers, increases care utilization, and reduces ER visits.”

“While GLP-1 drugs are effective, 30% of users gain or lose less than 3% body weight. Digbi Health leverages its expertise in precision biology to improve these outcomes,” said Dr. Garima Sharma, VP of Care. “Adherence issues due to GI distress, cost, and access are common. We address these through holistic care and offer safe compounded GLP-1 options for those who cannot afford branded drugs or lose coverage, ensuring effective and equitable care.”

Addressing Employer Pain Points:

  • Improved GLP Adherence and Reduced GI Distress: Over 90% of patients reduce GI issues, improving medication adherence and weight loss outcomes.
  • Consolidation of Point Solutions: Digbi Health simplifies care, increasing utilization by 3X and reducing ER visits by 56%.

For more information on Digbi Health’s medically managed weight loss program, visit https://digbihealth.com/pages/partner

Contacts

Aniiket@digbihealth.com

Industry:

Digbi Health

Release Versions
English

Contacts

Aniiket@digbihealth.com

More News From Digbi Health

Digbi Health to Present Groundbreaking Study on Gut Microbiome's Role in Enhancing Endogenous GLP-1 Production at 2024 Obesity Society Conference

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Digbi Health, a leader in Precision Biology and personalized healthcare, has been invited to present a landmark study at the Obesity Society Conference. The study demonstrates how the Digbi Health program successfully alters the gut microbiome to produce compounds that increase the body's natural production of endogenous GLP-1 (glucagon-like peptide-1). This breakthrough approach shows promise in reducing GLP-1 medication dosages, improving weight loss, i...

Digbi Health Launches an SEC-regulated Offering, Giving Millions the Opportunity to Invest in Groundbreaking Genetics and Gut Microbiome-based Care for Obesity and Digestive Health

PALO ALTO, Calif.--(BUSINESS WIRE)--Digbi Health, a leader in Precision biology-based care for obesity, type 2 diabetes, and gastrointestinal health, is excited to announce its SEC-regulated raise. This initiative allows millions to invest in the company's mission to transform healthcare by expanding access to personalized, genetics-based, and gut microbiome-driven treatments. Opening Equity Participation and Expanding Access to Care For the first time, Digbi Health is offering equity participa...

Digbi Health Selected by State Public Health Insurance Trust to Manage Obesity Treatment Costs Amid Escalating GLP-1 Drug Expenses

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Digbi Health, a leader in Precision Biology for obesity and chronic disease management, today announced that a prominent public health insurance trust has chosen the company to manage the growing costs and effective utilization of GLP-1 weight-loss drugs for municipal and teachers union workers. This strategic partnership expands Digbi Health's employer offering, integrating its GLP-1 Obesity Management Solution across payers, pharmacy benefit managers (P...
Back to Newsroom